You are here: Industry Insights > Target

News List

An Overview of the Research Advancements in Bispecific Antibodies Dopine/PharmaSources
August 30, 2023
According to the Pharmacodia Database, currently, there have been 13 drugs approved worldwide in this field. However, Removab was withdrawn from the market in 2017 due to its strong immunogenicity and commercial reasons.
KRAS - Hot Cancer Target Inhibitors in Developing Neeta Ratanghayra
March 22, 2021
Mutant oncogenes play a key role in driving cancer progression, and this fact has set the stage for the discovery of targeted anticancer therapies.
Gene-targeted cancer drugs, slow release overcome resistance worldpharmanews
September 17, 2019
Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and ...
Novartis hits targets in late-stage QMF149 asthma trial pharmatimes
June 03, 2019
The combo is currently in development for the treatment of inadequately controlled asthma in patients who remain symptomatic despite current treatment.
Takeda sets target date to close $62B Shire deal biospectrumasia
November 19, 2018
The deal would be the largest-ever overseas acquisition by a Japanese company.Singapore Aiming to close its deal for Sh
Where do big-cap biopharmas stand on the M&A matrix? fiercepharma
May 30, 2018
Johnson & Johnson has the most bucks for biopharma M&A, Astellas the easiest target: analyst
Current Situation of Biosimilars in China I: A Focus on the Biosimilar Market in China Tang
December 11, 2017
According to the financial reports issued by global pharmaceutical giants in 2016, 7 biological drugs entered the list of global top 10 best-selling drugs.
argenx announces collaboration with Broteio Pharma to develop therapeutic antibody for severe autoim firstwordpharma
March 22, 2017
Breda, the Netherlands/Ghent, Belgium - argenx announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target...
X-Chem, Janssen Biotech Expand Discovery Alliance contractpharma
February 16, 2017
Will apply X-Chem’s DEX platform to identify novel modulators for inflammatory disease targets